D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2

Area of Science:

• Biochemistry
• Cancer Biology
• Metabolic Regulation

Background:

• Isocitrate dehydrogenases (IDH) interconvert isocitrate and alpha-ketoglutarate (α-KG).
• Mutant IDH1/2 in cancer produces D2-hydroxyglutarate (D2-HG), interfering with α-KG-dependent dioxygenases.
• The role of D2-hydroxyglutarate dehydrogenase (D2HGDH) in controlling D2-HG to α-KG conversion is unclear.

Purpose of the Study:

• Investigate the physiological role of D2HGDH in α-KG metabolism and epigenetic regulation.
• Determine the enzymatic activity of D2HGDH and its mutants found in diffuse large B-cell lymphoma.
• Elucidate the mechanism by which D2-HG influences α-KG levels and IDH activity.

Main Methods:

• Enzymatic assays for wild-type and mutant D2HGDH.
• Genetic manipulation (depletion and ectopic expression) of IDH2.
• Analysis of α-KG levels, histone/DNA methylation, and HIF1α hydroxylation.
• Metabolite profiling to assess D2-HG levels and impact.

Main Results:

• Wild-type D2HGDH elevates α-KG levels, affecting epigenetic modifiers and HIF1α hydroxylation.
• D2HGDH mutants identified in diffuse large B-cell lymphoma exhibit no enzymatic activity.
• D2-HG positively modulates mitochondrial IDH activity and induces IDH2 expression.
• Genetic depletion of IDH2 abolished D2HGDH effects; ectopic IDH2 rescued D2HGDH-deficient cells.

Conclusions:

• D2HGDH is linked to cancer pathogenesis and regulates IDH2 activity and α-KG-mediated epigenetic reprogramming.
• The study reveals a novel regulatory role for D2HGDH in mitochondrial metabolism.
• Findings provide insights into the pathogenesis of D2HGDH-deficient diseases.